These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 6918018

  • 1. Influence of mevinolin on experimental atherosclerosis in rabbits.
    Kritchevsky D, Tepper SA, Klurfeld DM.
    Pharmacol Res Commun; 1981 Nov; 13(10):921-6. PubMed ID: 6918018
    [No Abstract] [Full Text] [Related]

  • 2. Hypercholesterolemia persisting after distal ileal bypass: response to mevinolin.
    Illingworth DR, Connor WE.
    Ann Intern Med; 1984 Jun; 100(6):850-1. PubMed ID: 6562870
    [No Abstract] [Full Text] [Related]

  • 3. [Pharmacologic therapy of arteriosclerosis. II. New directions].
    Santafé Oroz J, Segarra Domènech J.
    Med Clin (Barc); 1985 Jan 26; 84(3):115-22. PubMed ID: 3919229
    [No Abstract] [Full Text] [Related]

  • 4. Regulation of plasma cholesterol by compactin and mevinolin.
    Nutr Rev; 1985 Sep 26; 43(9):266-8. PubMed ID: 3903562
    [No Abstract] [Full Text] [Related]

  • 5. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase.
    Tobert JA, Hitzenberger G, Kukovetz WR, Holmes IB, Jones KH.
    Atherosclerosis; 1982 Jan 26; 41(1):61-5. PubMed ID: 6918220
    [Abstract] [Full Text] [Related]

  • 6. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
    Slater EE, MacDonald JS.
    Drugs; 1988 Jan 26; 36 Suppl 3():72-82. PubMed ID: 3076125
    [Abstract] [Full Text] [Related]

  • 7. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.
    Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J.
    Proc Natl Acad Sci U S A; 1980 Jul 26; 77(7):3957-61. PubMed ID: 6933445
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H, Fager G.
    Clin Pharmacokinet; 1997 May 26; 32(5):403-25. PubMed ID: 9160173
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of colestipol (U-26,597A) on experimental atherosclerosis in rabbits.
    Kritchevsky D, Kim HK, Tepper SA.
    Proc Soc Exp Biol Med; 1973 Jan 26; 142(1):185-8. PubMed ID: 4683239
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias.
    Aronson JK, Ng LL.
    Q J Med; 1990 Feb 26; 74(274):111-5. PubMed ID: 2111916
    [No Abstract] [Full Text] [Related]

  • 19. Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.
    Grundy SM, Bilheimer DW.
    Proc Natl Acad Sci U S A; 1984 Apr 26; 81(8):2538-42. PubMed ID: 6371816
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.